Skip to main content

Table 1 Baseline characteristics of 149 patients

From: Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy

Characteristics Number (%) Median (range)
Age (years)   61 (36–75)
  ≤ 65 95 (63.8%)  
 >65 54 (36.2%)  
Sex
 Male 111 (74.5%)  
 Female 38 (25.5%)  
Smoking
 Never 60 (40.3%)  
 Ever 89 (59.7%)  
ECOG PS
 0 73 (49.0%)  
 1 76 (51.0%)  
Histological type
 Adenocarcinoma 94 (63.1%)  
 Squamous 55 (36.9%)  
Lesion type
 Central 78 (52.3%)  
 Peripheral 71 (47.7%)  
Clinical stage
 IIIB 69 (46.3%)  
 IV 80 (53.7%)  
CEA
 Normal 95 (63.8%)  
 Increased 54 (36.2%)  
Albumin
 Decreased 50 (33.6%)  
 Normal 99 (66.4%)  
WBC (× 109/L)   7.6 (3.6–12)
LMR   3.25 (0.98–12.5)
NLR   2.78 (1.05–8.14)
PLR   143 (35–352)
SUVmax   11.8 (3.3–28.5)
  1. ECOG PS Eastern Cooperative Oncology Group Performance Status, CEA carcinoembryonic antigen, WBC white blood cell, LMR lymphocyte-monocyte ratio, NLR neutrophil-lymphocyte ratio, PLR platelet-lymphocyte ratio, SUVmax maximum standardized uptake value